A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants - Trial NCT06406348
Access comprehensive clinical trial information for NCT06406348 through Pure Global AI's free database. This Phase 1 trial is sponsored by Aliada Therapeutics and is currently Not yet recruiting. The study focuses on Alzheimer Disease. Target enrollment is 52 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Aliada Therapeutics
Timeline & Enrollment
Phase 1
May 01, 2024
Dec 01, 2024
Primary Outcome
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Summary
This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending
 dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of
 intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female
 participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06406348
Non-Device Trial